JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 77 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $60,000 | -96.0% | 12,200 | -95.0% | 0.00% | -94.3% |
| Q1 2019 | $1,514,000 | +60.6% | 244,300 | -12.7% | 0.07% | +7.7% |
| Q4 2018 | $943,000 | -44.2% | 279,900 | +7.7% | 0.06% | -33.0% |
| Q3 2018 | $1,689,000 | +2.2% | 259,857 | +20.5% | 0.10% | 0.0% |
| Q2 2018 | $1,652,000 | +22.5% | 215,700 | +257.1% | 0.10% | +12.8% |
| Q1 2018 | $1,349,000 | -29.7% | 60,400 | -59.9% | 0.09% | -16.5% |
| Q4 2017 | $1,918,000 | -24.1% | 150,500 | -7.2% | 0.10% | -23.7% |
| Q3 2017 | $2,527,000 | +43.8% | 162,200 | +29.4% | 0.14% | +25.0% |
| Q2 2017 | $1,757,000 | +30.6% | 125,300 | +104.7% | 0.11% | +27.1% |
| Q1 2017 | $1,345,000 | – | 61,200 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |